AR128393A1 - Uso novedoso de agonistas del receptor de melanocortina 1 - Google Patents

Uso novedoso de agonistas del receptor de melanocortina 1

Info

Publication number
AR128393A1
AR128393A1 ARP230100222A ARP230100222A AR128393A1 AR 128393 A1 AR128393 A1 AR 128393A1 AR P230100222 A ARP230100222 A AR P230100222A AR P230100222 A ARP230100222 A AR P230100222A AR 128393 A1 AR128393 A1 AR 128393A1
Authority
AR
Argentina
Prior art keywords
melanocortin
receptor agonists
novel use
pyrrolidin
medicament
Prior art date
Application number
ARP230100222A
Other languages
English (en)
Inventor
Masahiro Kondo
Tsuyoshi Suzuki
Yuko Kawano
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of AR128393A1 publication Critical patent/AR128393A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)

Abstract

Un medicamento para el tratamiento o la prevención de una enfermedad pulmonar intersticial, y de una enfermedad o un síntoma acompañado de esclerosis sistémica en un sujeto, donde dicho medicamento comprende, como un ingrediente eficaz, ácido 1-{2-[(3S,4R)-1-{[(3R,4R)-1-ciclopentil-3-fluoro-4-(4-metoxifenil)pirrolidin-3-il]carbonil}-4-(metoximetil)pirrolidin-3-il]-5-(trifluorometil)fenil}piperidin-4-carboxílico, o una sal o un cocristal farmacéuticamente aceptable del mismo.
ARP230100222A 2022-01-31 2023-01-31 Uso novedoso de agonistas del receptor de melanocortina 1 AR128393A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2022013759 2022-01-31

Publications (1)

Publication Number Publication Date
AR128393A1 true AR128393A1 (es) 2024-04-24

Family

ID=87471778

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100222A AR128393A1 (es) 2022-01-31 2023-01-31 Uso novedoso de agonistas del receptor de melanocortina 1

Country Status (3)

Country Link
AR (1) AR128393A1 (es)
TW (1) TW202340169A (es)
WO (1) WO2023145959A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6977185B2 (ja) * 2018-12-28 2021-12-08 田辺三菱製薬株式会社 ピロリジン化合物の結晶
WO2021251452A1 (ja) * 2020-06-10 2021-12-16 田辺三菱製薬株式会社 光線性皮膚疾患の予防又は治療剤

Also Published As

Publication number Publication date
TW202340169A (zh) 2023-10-16
WO2023145959A1 (ja) 2023-08-03

Similar Documents

Publication Publication Date Title
Samuel et al. Anti‐fibrotic actions of relaxin
Yang et al. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways
CA2789665A1 (en) Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
NO20051934L (no) Sfingosin-1-fosfatreseptoragonister ved behandling av demyelinerende lidelser.
US20050277629A1 (en) Methods for the treatment of synucleinopathies (Lansbury)
CL2021000491A1 (es) Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas
KR20090088854A (ko) 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도
AR065120A1 (es) Compuesto de aril pirazol azoespirodecanona, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
JP2013006854A5 (es)
JP2008508265A5 (es)
AR076400A1 (es) Formulaciones liquidas de sales de 1-(2-(2,4-dimetilfenilsulfanil)fenil)piperazina, uso, la sal y recipiente
AR068947A1 (es) Inhibidor de la proteina activadora de la 5- lipoxigenasa (flap), composiciones farmaceuticas, sales y solvatos
RU2008135979A (ru) Соединения гидроксиакрилаимда
RU2015144676A (ru) Применение рецептора антагониста ер4 для лечения хрящевой болезни
EA025948B1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR
Abd-Elaziz et al. Revisiting matrix metalloproteinase 12: its role in pathophysiology of asthma and related pulmonary diseases
JP2009532438A5 (es)
PH12021550170A1 (en) Pharmaceutical dosage form which can be adminitered orally and has modified release
WO2015111666A1 (ja) メガリン拮抗剤
JP2020510071A (ja) 特発性肺線維症の治療
AR128393A1 (es) Uso novedoso de agonistas del receptor de melanocortina 1
WO2020128614A9 (en) Method for treating interstital lung disease
AR036265A1 (es) Uso de bibn4096 en combinacion con otros farmacos antimigranosos para el tratamiento de migrana
BR112023005987A2 (pt) Composição farmacêutica, preparação farmacêutica, método de tratamento de uma doença ou disfunção associada à atividade de kdm1a em um paciente com sua necessidade, método de inibição de kdm1a e método para suprimir a proliferação de células mieloides malignas em um sujeito com sua necessidade